Rxivist logo

An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon

By Jie Zhu, Yong-Qiang Deng, Xin Wang, Xiao-Feng Li, Na-Na Zhang, Zurui Liu, Bowen Zhang, Cheng-Feng Qin, Zhengwei Xie

Posted 02 May 2020
bioRxiv DOI: 10.1101/2020.05.02.074021

The pandemic COVID-19 has spread to all over the world and greatly threatens safety and health of people. COVID-19 is highly infectious and with high mortality rate. As no effective antiviral treatment is currently available, new drugs are urgently needed. We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs. We found liquiritin significantly inhibit replication of SARS-CoV-2 in Vero E6 cells with EC50 = 2.39 μM. Mechanistically, we found liquiritin exerts anti-viral function by mimicking type I interferon. Upregulated genes induced by liquiritin are enriched in GO categories including type I interferon signaling pathway, negative regulation of viral genome replication and etc. In toxicity experiment, no death was observed when treated at dose of 300 mg/kg for a week in ICR mice. All the organ indexes but liver and serum biochemical indexes were normal after treatment. Liquiritin is abundant in licorice tablet (~0.2% by mass), a traditional Chinese medicine. Together, we recommend liquiritin as a competitive candidate for treating COVID-19. We also expect liquiritin to have a broad and potent antiviral function to other viral pathogens, like HBV, HIV and etc. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 2,171 times
  • Download rankings, all-time:
    • Site-wide: 5,856
    • In systems biology: 102
  • Year to date:
    • Site-wide: 21,807
  • Since beginning of last month:
    • Site-wide: 7,196

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News